|Videos|September 7, 2021
CLL: Final Thoughts
An expert panel provides their final thoughts about the future of the chronic lymphocytic leukemia (CLL) treatment landscape.
Advertisement
Episodes in this series
Advertisement
Related to this article
Matthew S. Davids, MD, MMSc, discusses data from BRUIN CLL-322 and how they may shake up the CLL treatment paradigm.
CHMP recommends pirtobrutinib for CLL across all treatment lines after phase 3 trials showed strong efficacy and a favorable safety profile.
Advertisement
Advertisement
Trending on OncLive
1
Patient-Level Data Show Extended OS Advantage With DCVax-L vs External Controls in Glioblastoma
2
Zoldonrasib Combinations Show Compelling Antitumor Activity in RAS G12D–Mutant Metastatic PDAC
3
FDA Approves Subcutaneous Isatuximab Delivered Via On-Body Delivery System for Multiple Myeloma
4
Ensartinib Reduces Recurrence Risk After Resection in ALK-Positive NSCLC
5